Dechra Pharmaceuticals PLC Appointment of Chief Financial Officer (5470R)
October 30 2019 - 3:00AM
UK Regulatory
TIDMDPH
RNS Number : 5470R
Dechra Pharmaceuticals PLC
30 October 2019
30 October 2019
Dechra(R) Pharmaceuticals PLC
(Dechra, Company or the Group)
Board Change
Appointment of Chief Financial Officer
Dechra is pleased to announce that Paul Sandland, acting Chief
Financial Officer since April this year, has been appointed as an
Executive Director and permanent Chief Financial Officer of the
Company with immediate effect.
Paul qualified as a Chartered Certified Accountant with KPMG in
2005 and joined Dechra in 2010 as Group Financial Controller.
Between 2012 and 2013 Paul was Acting CFO prior to becoming the
Group's Dechra Veterinary Products EU finance director, a position
he held until April this year.
Commenting on the appointment Tony Rice, Chairman, said:
"I am delighted to confirm Paul's appointment as Dechra's
permanent CFO. Paul has proven to be an excellent acting CFO and,
over a much longer period, has clearly demonstrated a strong
practical understanding of all parts of the Group and its needs, as
well as an independence of mind and strong technical, strategic and
commercial skills. The Company followed a rigorous process before
appointing Paul. He has been a core part of the Dechra leadership
team over the last ten years."
Paul Sandland, Chief Financial Officer added:
"I am delighted to take on the CFO role on a permanent basis.
Dechra is a wonderful, well invested Company with global brands and
significant growth opportunities ahead of it. Whilst I have been
privileged to be part of the development of Dechra over the last
ten years, I am confident that Dechra continues to have enormous
potential and, working alongside the talented pool of people we
have around the business at all levels, I look forward to helping
unlock that potential."
Paul Sandland currently has a beneficial interest in the Company
totalling 5,069 shares which represents 0.005% of the current
issued share capital.
There are no other disclosures required in respect of this
appointment pursuant to Listing Rule 9.6.13R.
Enquiries to:
TooleyStreet Communications Ltd
Fiona Tooley, Director
Mobile: +44 (0) 7785 703 523
e-mail: fiona@tooleystreet.com
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Office: +44 (0) 1606 814 730
e-mail: corporate.enquiries@dechra.com
About Dechra
Dechra is a global veterinary pharmaceuticals and relates
products business. Our expertise is in the development, manufacture
and sales and marketing of high quality products exclusively for
veterinarians worldwide. Dechra's business is unique as the
majority of its products are used to treat medical conditions for
which there is no other effective solution or have a clinical or
dosing advantage over competitor products.
For more information please visit: www.dechra.com
Stock Code: Full Listing (Pharmaceuticals): DPH
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOALFFIVIALAFIA
(END) Dow Jones Newswires
October 30, 2019 03:00 ET (07:00 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From Apr 2024 to May 2024
Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart
From May 2023 to May 2024